Last updated on October 2018

A Six Week Efficacy Safety and Tolerability Study of V565 in Crohn's Disease


Brief description of study

The purpose of this study is to evaluate the efficacy and safety of V565 in participants with active Crohn's Disease.

Detailed Study Description

This study will be a multiple-site, double-blind, placebo-controlled, parallel-group study in approximately 126 subjects with a confirmed diagnosis of CD for at least three months and have CD involving the ileum and/or colon. Following a screening period of up to 28 days, subjects will be randomly allocated into one of two treatment arms: either V565 or placebo using a 2:1 active:placebo ratio for a treatment period of 6 weeks.

Subjects will be treated with study drug as an add-on to any permitted stable medications already being taken for CD.

Clinical Study Identifier: NCT02976129

Find a site near you

Start Over

LKH - Universitatsklinikum

Salzburg, Austria
0.84miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.